Bioaffinity technologies announces publication of results of clinical trial in peer-reviewed journal respiratory research

San antonio--( business wire )--bioaffinity technologies, inc. (nasdaq: biaf; biafw) today announced publication of “ detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning ” detailing results of the company's clinical trial for its non-invasive diagnostic cypath® lung in respiratory research, one of the leading peer-reviewed open access journals in the field of respiratory medicine.
BIAF Ratings Summary
BIAF Quant Ranking